Securities code: 300110 securities abbreviation: Huaren Pharmaceutical Co.Ltd(300110) Announcement No.: 2022-001 Huaren Pharmaceutical Co.Ltd(300110)
Performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021.
2. Expected performance: rising in the same direction
The current reporting period of the project is the same period of last year
Attributable to shareholders of listed companies increased by 32.10% – 58.52% over the same period last year
Net profit: 94.624 million yuan; Profit: 125-150 million yuan
After deducting non recurring profits and losses, it increased by 23.95% – 57.75% over the same period of the previous year
Net profit: 88.7455 million yuan; Profit: 110-140 million yuan
2、 Communication with accounting firms
There is no difference between the company and the accounting firm on the content of this performance forecast.
3、 Explanation of performance change reasons
1. In the same period last year, the company’s drug business was affected to some extent due to the epidemic. During the reporting period, as the epidemic situation in China was effectively controlled, the company continued to integrate and improve sales channels, actively explore incremental markets, strengthen market access, and actively respond to the national, provincial and prefecture level centralized procurement policies. Drug sales increased compared with the same period last year.
2. During the reporting period, the company actively promoted the layout of the whole pharmaceutical and health industry chain, and the business of the pharmaceutical business sector grew steadily, contributing some profits.
3. In November 2020, the company acquired 100% equity of Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke pharmaceutical packaging Co., Ltd., which were included in the consolidated statements in November 2020, and contributed some profits during the reporting period.
4. In August 2021, the company acquired 100% equity of Xi’an hengjuxing Pharmaceutical Co., Ltd. through its wholly-owned subsidiary Xi’an Qujiang Huaren Pharmaceutical Co.Ltd(300110) Co., Ltd., and indirectly held 100% equity of Anhui Xingxing Pharmaceutical Co., Ltd., which has been included in the consolidated statements since August 2021, contributing part of the profits during the reporting period.
4、 Other relevant instructions
This performance forecast is the result of preliminary calculation by the company’s financial department. Without audit by the audit institution, the specific financial data will be disclosed in detail in the company’s 2021 annual report. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Board of directors January 10, 2002
